{"id":"betahistine-extended-release-formulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Betahistine works primarily by antagonizing H3 receptors on histaminergic neurons, which increases histamine release and subsequent H1 receptor activation in the inner ear vasculature. This leads to improved microcirculation in the cochlea and vestibular system, reducing endolymphatic hydrops and alleviating symptoms of vertigo and inner ear dysfunction. The extended-release formulation provides sustained drug levels to maintain therapeutic benefit over a longer dosing interval.","oneSentence":"Betahistine is a histamine H1 receptor agonist and H3 receptor antagonist that increases blood flow to the inner ear and reduces endolymphatic pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:25.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Menière's disease (vertigo, tinnitus, hearing loss)"},{"name":"Vestibular vertigo"}]},"trialDetails":[{"nctId":"NCT01168336","phase":"PHASE1","title":"Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects","status":"COMPLETED","sponsor":"OBEcure Ltd.","startDate":"2010-07","conditions":"Healthy","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vasomotal","Agiserc®","SERC","Betahistine"],"phase":"marketed","status":"active","brandName":"Betahistine Extended Release formulation","genericName":"Betahistine Extended Release formulation","companyName":"OBEcure Ltd.","companyId":"obecure-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Betahistine is a histamine H1 receptor agonist and H3 receptor antagonist that increases blood flow to the inner ear and reduces endolymphatic pressure. Used for Menière's disease (vertigo, tinnitus, hearing loss), Vestibular vertigo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}